This review synthesizes the pharmacological mechanisms, clinical findings, and safety data of tirzepatide in OSAS management
Most users experience only mild symptoms, but some may face more severe reactions
They focus on three signals: symptom trajectories, objective labs, and the rate of weight loss
Muscle cramps are not listed as a common side effect in FDA labeling for GLP-1 receptor agonists, and clinical trials have not shown significantly higher rates compared to placebo
On the other hand, oral pills are a convenient and affordable option for long-term use
Eating smaller, nutrient-dense meals and staying hydrated (64+ oz water daily) can further enhance results